Keywords : Acute ischemic stroke
European Journal of Molecular & Clinical Medicine,
2020, Volume 7, Issue 8, Pages 4773-4777
Background: Stroke is the second leading cause of death in the world in the last two decades. The present study was conducted to evaluate HbA1C as a valid tool for risk assessment in ischemic stroke and TIA.
Materials & Methods: 50 patients who were diagnosed with acute ischemic stroke or TIA, were included. Diagnosis of acute ischemic stroke was made on CT/MRI scan. Estimation of HbA1C was done by photometric test using ion exchange resin. Estimation of blood glucose level was done by glucose oxidase method.
Results: Group I was non- diabetic having 10, group II was pre- diabetic having 8 and group III was diabetic having 22 patients. There were 30 (60%) males and 20 (40%) females. In group A there were 6 males and 4 females, group B had 10 males and 8 females while in group C there were 14 males and 8 females. The sex distribution amongst the three groups did not reveal any statistical difference, and hence all the three groups were comparable.
Conclusion: HbA1C is a novel marker for determining the glycaemic status of a person. In cases of acute ischemic stroke and TIA, HbA1C should be used as a screening tool in determining the previous glycaemic status, prevalence of prediabetes and differentiate it from stress hyperglycaemia.